Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

Data on efficacy and safety of azacitidine in acute myeloid leukemia (AML) with >30 % bone marrow (BM) blasts are limited, and the drug can only be used off-label in these patients. We previously reported on the efficacy and safety of azacitidine in 155 AML patients treated within the Austrian Az...

Descripción completa

Detalles Bibliográficos
Autores principales: Pleyer, Lisa, Burgstaller, Sonja, Girschikofsky, Michael, Linkesch, Werner, Stauder, Reinhard, Pfeilstocker, Michael, Schreder, Martin, Tinchon, Christoph, Sliwa, Thamer, Lang, Alois, Sperr, Wolfgang R., Krippl, Peter, Geissler, Dietmar, Voskova, Daniela, Schlick, Konstantin, Thaler, Josef, Machherndl-Spandl, Sigrid, Theiler, Georg, Eckmüllner, Otto, Greil, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176957/
https://www.ncbi.nlm.nih.gov/pubmed/24951123
http://dx.doi.org/10.1007/s00277-014-2126-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176957/
https://www.ncbi.nlm.nih.gov/pubmed/24951123
http://dx.doi.org/10.1007/s00277-014-2126-9

Ejemplares similares